PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
R&D reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive risk.
3.54%
G&A change of 3.54% while RVPH maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
-10.44%
Operating expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine advantage.
-10.44%
Total costs reduction while RVPH shows 115.84% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine advantage.
721.68%
D&A change of 721.68% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
11.90%
EBITDA growth while RVPH declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth while RVPH declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
10.28%
Pre-tax income growth while RVPH declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth while RVPH declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS growth while RVPH declines. John Neff would investigate advantages.
10.49%
Diluted EPS growth while RVPH declines. John Neff would investigate advantages.
2.21%
Share count reduction exceeding 1.5x RVPH's 600.27%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.